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Abstract
Background: Sleeping sickness due to Trypanosoma brucei (T.b.) gambiense is still a major public health problem in some
central African countries. Historically, relapse rates around 5% have been observed for treatment with melarsoprol, widely
used to treat second stage patients. Later, relapse rates of up to 50% have been recorded in some isolated foci in Angola,
Sudan, Uganda and Democratic Republic of the Congo (DRC). Previous investigations are not conclusive on whether
decreased sensitivity to melarsoprol is responsible for these high relapse rates. Therefore we aimed to establish a parasite
collection isolated from cured as well as from relapsed patients for downstream comparative drug sensitivity profiling. A
major constraint for this type of investigation is that T.b. gambiense is particularly difficult to isolate and adapt to classical
laboratory rodents.
Methodology/Principal Findings: From 360 patients treated in Dipumba hospital, Mbuji-Mayi, D.R. Congo, blood and
cerebrospinal fluid (CSF) was collected before treatment. From patients relapsing during the 24 months follow-up, the same
specimens were collected. Specimens with confirmed parasite presence were frozen in liquid nitrogen in a mixture of
Triladyl, egg yolk and phosphate buffered glucose solution. Isolation was achieved by inoculation of the cryopreserved
specimens in Grammomys surdaster, Mastomys natalensis and SCID mice. Thus, 85 strains were isolated from blood and CSF
of 55 patients. Isolation success was highest in Grammomys surdaster. Forty strains were adapted to mice. From 12 patients,
matched strains were isolated before treatment and after relapse. All strains belong to T.b. gambiense type I.
Conclusions and Significance: We established a unique collection of T.b. gambiense from cured and relapsed patients,
isolated in the same disease focus and within a limited period. This collection is available for genotypic and phenotypic
characterisation to investigate the mechanism behind abnormally high treatment failure rates in Mbuji-Mayi, D.R. Congo.
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Introduction
Within the group of tsetse (Glossina sp) transmitted African
trypanosomes, Trypanosoma brucei (T.b.) gambiense and T.b. rhodesiense
are the two causative agents of sleeping sickness. This disease, also
called human African trypanosomiasis (HAT) constitutes a serious
public health threat in Africa, particularly in east and central Africa.
In 2006, among 3 million people screened, almost 12,000 HAT
patients were diagnosed most of them infected with T.b. gambiense
[1]. The infection progresses from the first, haemo-lymphatic stage
to the second, meningo-encephalitic stage once parasites reach the
central nervous system. Without treatment, the disease is almost
100% fatal. No vaccine is expected in the near future [2].
Melarsoprol is still the most widely used drug for treatment of
second stage gambiense and rhodesiense HAT, although for gambiense
HAT, the combination of eflornithine and nifurtimox is now on
the market and will hopefully replace melarsoprol [3]. Historically,
an overall relapse rate of 5% has been observed for treatment with
melarsoprol [4]. Later, relapse rates of up to 50% after
melarsoprol treatment have been noted in some isolated foci in
Angola, Sudan, Uganda and Democratic Republic of the Congo
(DRC) [5–10].
In laboratory models, in vitro and in vivo resistance of T.b. brucei to
melarsoprol has been ascribed to reduced uptake of the drug via
the P2 nucleoside transporter [11,12] although the mechanism
underlying melarsoprol resistance may be much more complex
[13].
Several phenotypic and genotypic studies have been undertaken
to explain the alarmingly high relapse rates encountered in the
field by reduced sensitivity of T.b. gambiense strains to melarsoprol
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[14–17]. Though, no conclusive results could be obtained,
partially because of bias in parasite strain selection. To confirm
or reject the hypothesis of resistance against melarsoprol
underlying high relapse rates, it is not sufficient to study parasites
from relapsing patients only or from patients with unknown
treatment outcome. Rather, comparative in vitro and/or in vivo
drug sensitivity profiling should be carried out on isolates collected
in the same disease focus from both cured and relapsing patients.
A major constraint for this type of investigation is the fact that T.b.
gambiense is particularly difficult to isolate and adapt to rodents and
to in vitro culture.
In a previous study, we reported on improved isolation of T.b.
gambiense by inoculation of freshly collected blood and cerebrospi-
nal fluid into the ticket rat Grammomys (G.) surdaster [18]. Since these
rats are not readily available at places where HAT patients are
treated, cryopreservation of patient specimens prior to inoculation
into these susceptible rodents is necessary. Maina and co-workers
reported on an improved cryopreservation method of T.b.
gambiense based on a cryomedium for bull semen, Triladyl
(MiniTu ¨B, Germany) [19]. By cryopreserving patient blood in
Triladyl before inoculation into immunosuppressed Mastomys (M.)
natalensis and into severe combined immune deficiency (SCID)
mice, they isolated with 38% success rate T.b. gambiense strains that
underwent further genotypic and phenotypic characterisation
[14,20].
Taking advantage of a prospective study on the improvement of
follow-up of gambiense patients in Mbuji-Mayi (RDC) [6], we
decided to isolate T.b. gambiense strains from cured patients before
treatment and from relapsing patients before treatment and at the
time of relapse, in order to establish a unique collection of parasite
strains for subsequent comparative drug sensitivity profiling. We
here report on the isolation in G. surdaster, M. natalensis and SCID
mice of T.b. gambiense strains starting from blood and cerebrospinal
fluid (CSF) cryopreserved in Triladyl and on subsequent




The collection of patients’ specimens was approved by the
Ethical Committee of the Institute of Tropical Medicine
(04441472) and of the Ministry of Health of DRC. Written
informed consent was obtained from the patients prior to
collection of the specimens. Patients were informed about the
objectives and protocol of the study. Experiments on animals were
approved by the Veterinary Ethical Committee of the Institute of
Tropical Medicine (PAR-022) and adhere to the European
Commission Recommendation on guidelines for the accommo-
dation and care of animals used for experimental and other
scientific purposes (18 June 2007, 2007/526/EG) and the Belgian
National law on the protection of animals under experiment.
Patients
Patients belong to a cohort included in a follow-up study
(THARSAT study) conducted in Dipumba hospital, Mbuji-Mayi,
East Kasai Province, DRC between May 2005 and May 2007
(Figure 1). Details on patients, applied treatment regimens, follow-
up and treatment outcome definitions have been published
elsewhere [6]. Of the 360 patients included, 93 (26%) experienced
a confirmed relapse after treatment with a melarsoprol containing
regimen, 1 after pentamidine and 1 after eflornithine treatment.
Diagnosis at inclusion and at the moment of relapse was confirmed
by demonstration of the parasite in lymph node aspirate, venous
blood or CSF [6]. This study was approved by the Ethical
Committee of the University of Antwerp and of the Ministry of
Health of DRC. Written informed consent was obtained from the
patients prior to collection of the specimens. Patients were
informed about the objectives and protocol of the study.
Specimens were collected and cryopreserved from every consent-
ing patient before treatment. Patients were monitored for
treatment outcome at 3, 6, 12, 18 and 24 months after treatment.
From patients that relapsed, most of them with confirmed
recurrence of the parasite, specimens were again cryopreserved.
Triladyl-egg yolk-phosphate buffered saline glucose (TEP)
cryomedium
One volume of aseptically collected egg yolk was mixed with 3
volumes of Triladyl and 3 volumes of phosphate buffered saline
glucose (PSG, 7.5 g/l Na2HPO4.2H2O, 0.34 g/l NaH2PO4.H2O,
2.12 g/l NaCl, 10 g/l D-glucose, pH 8). The mixture was divided
over 2 ml aliquots and kept frozen at 220uC until use.
Cryopreservation of venous blood and cerebrospinal
fluid
One and a half milliliter of blood on heparin or of CSF was
dispensed in microcentrifugation tubes and centrifuged for
5 minutes at 5.200 or 7.244 g, depending on the centrifuge in
use. For blood, the plasma was removed and 250 ml of the buffy
coat were transferred into 2 ml Sarstedt screw cap micro tubes
(Sarstedt, Nu ¨mbrecht, Germany) filled with 250 ml of the TEP
cryomedium. For CSF, the supernatant was removed leaving
about 300 ml of sediment in each tube. The sediment was mixed
with 300 ml of TEP cryomedium and 500 ml were transferred into
2 ml Sarstedt screw cap micro tubes. Samples mixed with
cryomedium were frozen in the vapour phase of liquid nitrogen
for 1 hour where after they were dipped into the liquid phase of
the gas until further use. Cryopreserved specimens were shipped to
the Institut National de Recherche Biome ´dicale (INRB) in
Kinshasa where isolation in rodents took place.
Author Summary
Human African trypanosomiasis, or sleeping sickness, is
still a major public health problem in central Africa.
Melarsoprol is widely used for treatment of patients where
the parasite has already reached the brain. In some regions
in Angola, Sudan, Uganda and Democratic Republic of the
Congo, up to half of the patients cannot be cured with
melarsoprol. From previous investigations it is not yet clear
what causes these high relapse rates. Therefore we aimed
to establish a parasite collection isolated from cured as
well as relapsed patients for downstream comparative
drug sensitivity profiling. From 360 sleeping sickness
patients, blood and cerebrospinal fluid (CSF) was collected
before treatment and along the prescribed 24 months
follow-up. Blood and CSF were inoculated in thicket rats
(Grammomys surdaster), Natal multimammate mice (Mas-
tomys natalensis) and immunodeficient laboratory mice
(Mus musculus). Thus, we established a unique collection of
Trypanosoma brucei gambiense type I parasites, isolated in
the same disease focus and within a limited period,
including 12 matched strains isolated from the same
patient before treatment and after relapse. This collection
is now available for genotypic and phenotypic character-
isation to investigate the mechanism behind abnormally
high treatment failure rates in Mbuji-Mayi, Democratic
Republic of the Congo.
T.b. gambiense from Cured and Relapsed Patients
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Cryopreserved blood and CSF specimens were thawed in a
water bath at 37uC and 300 ml were inoculated intraperitoneally
(i.p.) into young (1–2 months, both sexes, 20–30 g) M. natalensis
and adult (9–12 months, both sexes, 30–40 g) G. surdaster. Two
days before inoculation, the M. natalensis were immunosuppressed
with 200 mg/kg body weight cyclophosphamide (Endoxan,
Baxter, Lessing, Belgium). Immunosuppression with the same
dose was repeated after 7 days. G. surdaster rats were not
immunosuppressed. Parasitemia was monitored three times a
week during the first month and further two times a week for at
least 2 months by microscopic examination of 5 ml fresh tail blood.
When first peak parasitemia was ,10
6/ml, blood from the
parasitemic animal was subinoculated into a naive animal which
was monitored as described above. When parasitemia reached
about 10
6.9/ml according to the matching method [21], the
animal was euthanised with an i.p. injection of sodium
pentobarbital at 350 mg/kg body weight (Nembutal, CEVA
Sante ´ Animale, Brussels, Belgium). Blood was taken by heart
puncture on heparin (Heparin LEO, LEO Pharma, Wilrijk,
Belgium) and aliquots of 250 ml were mixed with 250 ml TEP
cryomedium and frozen in liquid nitrogen. After one week, one
cryovial of each isolate was thawed in a water bath at 37uC and
checked in phase contrast microscopy for viability of the
cryopreserved trypanosomes. From all isolated strains, copy
cryostabilates were deposited in the cryobank of ITM.
Figure 1. Map of the Democratic Republic of the Congo. The town of Mbuji-Mayi with a 100 km perimeter where the patients in the THARSAT
study were recruited (courtesy of Janey Messina, University of North Carolina, Department of Geography).
doi:10.1371/journal.pntd.0001025.g001
T.b. gambiense from Cured and Relapsed Patients
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Balb/C and SCID mice)
Adaptation of isolates to laboratory mice took place at INRB in
Kinshasa, at the Institute of Tropical Medicine in Antwerp (ITM)
and at the Swiss Tropical and Public Health Institute in Basel
(STPH). At INRB, adult female NMRI mice were immunosup-
pressed as described above prior to inoculation. Stabilates were
thawed, trypanosome viability was checked under the microscope
and from each stabilate 0.5 ml was inoculated i.p. in one mouse.
Parasitemia was checked regularly for up to 30 days as described
above. Immunosuppression with the same dose was repeated every
5 days. When parasitemia reached 10
7.8/ml within 12 days post
infection, the strain was considered adapted, the mouse was
euthanised, blood was taken by heart puncture and 0.2 ml
cryostabilates were prepared with TEP cryomedium as described
above. At ITM, immune suppressed adult female OF-1 mice were
used for adaptation and glycerol 10% was used as cryomedium. At
STPH, some isolates were adapted in a similar manner to adult
female immunosuppressed Balb/C and to immunodeficient adult
female SCID mice. From all adapted strains, copy cryostabilates
were deposited in the cryobank of ITM.
Identification of the subspecies
During adaptation of the strains in M. musculus, 200 ml of blood
were mixed with an equal volume of AS1 buffer (Qiagen, Hilden,
Germany). DNA was extracted with the Maxwell 16 Tissue DNA
Purification Kit (Promega, Madison, Wisconsin, USA) and PCR
analysed for the T.b. gambiense specific TgsGP and for the T.b.
rhodesiense specific SRA according to the published protocols
[22,23].
Results
At the moment of inclusion in the study, 41 patients were in first
and 319 were in second stage of the disease. From these patients, a
total of 436 blood and 588 CSF specimens were cryopreserved
before treatment. During the 24 months follow-up, 1 first stage
patient and 94 second stage patients experienced a relapse with
confirmed presence of trypanosomes. From these relapsed
patients, a total of 44 blood and 258 CSF specimens were
cryopreserved (table 1). Specimens were cryopreserved immedi-
ately after detection of the trypanosomes in order to limit the time
between specimen collection and cryopreservation (typically less
than 30 minutes). Specimens cryopreserved at Dipumba hospital
were shipped within two weeks to INRB where they were
transferred from the dry liquid nitrogen shipper into a liquid
nitrogen tank.
Isolation of strains into G. surdaster, M. natalensis and SCID mice
started with specimens from the relapsing patients, obtained before
treatment and at the time of relapse. Isolation of strains from cured
patient specimens collected before treatment could only start with
a delay of 24 months when the test-of-cure had taken place and
had shown definite cure [6]. Some specimens were inoculated in
more than one rodent species and some were inoculated in more
than one animal of the same species. Table 2 summarises the
isolation results obtained according to the recipient rodent species
and the type of specimen inoculated. One hundred fifty one
specimens were inoculated in 215 G. surdaster, 58 specimens in 109
immunosuppressed M. natalensis and 19 specimens in 38 SCID
mice of which respectively 81, 17 and 5 became parasitemic. The
infection success rate (percentage of animals becoming parasitemic
after inoculation) was higher in G. surdaster (37.7%) than in M.
natalensis (15.6%) but not in SCID mice (13.2%). Infection success
rates were not different between blood and CSF. Infection success
rates were higher in animals inoculated with specimens from cured
than from relapsed patients and were respectively 37.5% and
27.1%. The mean time to first observed parasitemia in animals
that became parasitemic was 13.8 days post infection in G.
surdaster, 16.7 days in M. natalensis and 19.5 days in SCID with a
large variation (minimum 4 and maximum 52 days). Not all strains
that grew in the inoculated rodents reached high enough
parasitemia levels ($10
6/ml) to allow cryostabilisation, even after
2 to 4 subinoculations, but isolation success rate (number of
isolates as percentage of inoculated specimens) was much higher in
G. surdaster (46.4%) than in M. natalensis (17.2%) and SCID mice
(26.3%).
Adaptation of the strains isolated in G. surdaster and in M.
natalensis to M. musculus occurred at different places and in different
breeds, NMRI, Balb/C, OF-1 and SCID. The three first breeds
were immunosuppressed before inoculation and during follow-up.
In total, 72 animals were inoculated with cryostabilates from
which 61 M. musculus-adapted populations, representing 45
different strains, could be cryostabilised (Table 3). The adaptation
success rate (number of adapted populations as percentage of
inoculations) was 81.3% in NMRI, 75.0% in Balb/C, 87.5% in
OF-1 and 100.0% in SCID. All mouse adapted strains tested
positive in the TgsGP-PCR and negative in SRA-PCR and thus
belong to the T.b. gambiense type I (data not shown).
Table S1 summarises the collection of T.b. gambiense strains
isolated in Mbuji-Mayi, D.R. Congo, with some of their
characteristics. The collection consists of 85 T.b. gambiense strains
isolated from 1 first stage (patient nr 99) and 54 second stage
patients. Fifteen strains were isolated from 13 cured patients and
58 strains from 32 patients that relapsed after 10 days melarsoprol
or 14 days melarsoprol-nifurtimox combination treatment. The
rest of the strains were isolated from patients with probable relapse
(abnormal CSF but not confirmed parasitologically) and from
patients with incomplete follow-up. Nineteen strains originate
from patients that had already experienced a relapse after
melarsoprol treatment before inclusion in the THARSAT study.
The majority (58) of the strains could be isolated after a single
passage in G. surdaster, M. natalensis or SCID while for 26 strains
two passages and for one strain four passages were necessary.
From 12 relapsed patients, matched strains were isolated before
treatment and after relapse. Among the 40 strains so far adapted to
M. musculus, 12 were isolated from cured and 28 from relapsed
patients.
Discussion
The aim of the present study was to establish a collection of T.b.
gambiense strains isolated from a HAT focus with high treatment
failure rates and from relapsed as well as cured patients.






Stage Patients Relapses Blood CSF Blood CSF
First 41 1 123 0 4 6
Second 319 94 313 588 40 252
Total 360 95 436 588 44 258
CSF=cerebrospinal fluid.
doi:10.1371/journal.pntd.0001025.t001
T.b. gambiense from Cured and Relapsed Patients
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specimens. Since it was the intention to isolate bloodstream form
trypomastigote populations, methods that result in procyclic
populations, like the Kit for In Vitro Inoculation or the feeding
of teneral tsetse flies, were not suitable [24,25]. Inoculation of in
vitro culture medium containing a feeder layer of Microtus montanus
embryonic fibroblasts has been described as highly efficient for
isolation of bloodstream form trypomastigote populations from
CSF [26]. Since technical facilities in Dipumba hospital are rather
basic, an in vitro method to isolate bloodstream form trypomas-
tigotes could not be applied in the present study. Instead, we
combined two recently described methods for improved isolation
of T.b. gambiense. The first is based on the observation that G.
surdaster and immunosuppressed M. natalensis are more susceptible
to infection with T.b. gambiense than Mus musculus, the classical
laboratory mouse [18]. However, as for SCID mice, it was not
feasible to keep these animals close to the patients for the whole
study period. The second method allows to cryopreserve patient
blood and CSF in liquid nitrogen before inoculation into a
susceptible rodent [19]. Thus, it was possible to collect blood and
CSF from every patient in the THARSAT study before treatment
and to postpone isolation of the parasites until the definite
treatment outcome was known, i.e. $24 months for cured
patients.
Following this protocol, we obtained an isolation success rate of
46.7% in G. surdaster, compared to 17.9% in M. natalensis and
26.3% in SCID mice. The slightly lower success rate in G. surdaster
than observed in the former study (62%) can be explained by the
cryopreservation of the specimen prior to inoculation [18].
Particularly in specimens with low parasite numbers, the number
of live trypanosomes inoculated into the recipient rodent after
thawing the cryostabilate may not be sufficient to induce patent
parasitaemia. On the other hand, keeping the delay between
specimen collection and cryostabiliation short and concentrating
the parasites prior to addition of the cryomedium may have
contributed to the overall isolation success rate. Noteworthy is that
in some cases parasitaemia was only observed more than one
month after inoculation. Therefore, a two-month follow-up of the
inoculated animals is indicated. The present study confirms the
interest to use G. surdaster as primary host for in vivo isolation of T.b.
gambiense from HAT patients where after the isolated strains can be
further adapted to mice, preferably via SCID mice. To our
knowledge, INRB is the only institute with a breeding colony of
this thicket rat but because cryopreservation of patient specimens
prior to inoculation is compatible with high isolation success,
specimens collected in other HAT endemic countries could be sent
to Kinshasa for isolation of the parasites in G. surdaster.
For downstream genotypic and phenotypic characterisation of
isolated strains, it is important to limit the number of passages in
r o d e n t sa sm u c ha sp o s s i b l e ,a l t h o u g hs e l e c t i o nb i a si n t r o d u c e db y
cryopreservation and isolation cannot be excluded. Within the
current study, most strains underwent only one passage in G. surdaster
or M. natalensis before a primary isolate could be cryostabilised.
During further passages in different breeds of M. musculus,s o m e
strains were lost but for the majority adaptation was straightforward.
The majority of the strains within the collection presented here
were isolated from patients that relapsed after treatment with the
10 days melarsoprol treatment recommended by the International
Council for Trypanosomiasis Reseach and Control as first line
treatment of second stage T.b. gambiense patients in 2003 [27].
Within the THARSAT study, patients that relapsed from a
previous treatment for HAT were also included [6]. As a result, we
were able to isolate strains from patients with multiple relapses
after 10 days or 363 days melarsoprol (M10 or M3) and 14 days
melarsoprol-nifurtimox (MN) treatment, as well as from patients
that relapsed after melarsoprol (M10 or M3) treatment and that
got cured after subsequent 14 days treatment with eflornithine
(E14) or with the melarsoprol-nifurtimox combination. Most
importantly, the isolate collection contains 2612 paired strains
isolated from the same patients before treatment and at the time of
relapse. We consider this as a major achievement since this will
allow precise genotypic and phenotypic comparison of T.b.
gambiense strains isolated before and after treatment and of strains
isolated from cured and relapsed patients. All strains already
adapted to M. musculus belong to T.b. gambiense type I. Based on this
finding, coupled to the geographical location of Mbuji-Mayi, we
consider the other strains in the collection to be T.b. gambiense type
I as well. Genetic characterisation using microsatellite markers
together with analysis of possible mutations in the TbAT1 gene, are
foreseen during downstream in vivo drug sensitivity experiments, so
that the observed phenotypic diversity can be directly linked with
genetic diversity [28–30].





















G. surdaster Blood 49 76 29 38.2 15.1 (6–52) 25 51.0
CSF 102 139 52 37.4 13.1 (4–50) 45 44.1
M. natalensis Blood 21 40 8 20.0 17.7 (4–37) 3 14.3
CSF 37 69 9 13.0 16.0 (6–38) 7 18.9
SCID mouse CSF 19 38 5 13.2 19.5 (8–31) 5 26.3
doi:10.1371/journal.pntd.0001025.t002










NMRI 32 26 81.3
Balb/C 12 9 75.0
OF-1 16 14 87.5
SCID 12 12 100.0
doi:10.1371/journal.pntd.0001025.t003
T.b. gambiense from Cured and Relapsed Patients
www.plosntds.org 5 April 2011 | Volume 5 | Issue 4 | e1025In conclusion, we established a unique collection of T.b.
gambiense type I populations containing strains from cured and
from relapsed patients, isolated in the same HAT focus and within
a limited time period. This collection is now available for the
research community to conduct detailed genotypic and phenotypic
characterisation in order to confirm or reject the hypothesis that
resistance to melarsoprol is involved in the abnormally high
treatment failure rates observed in Mbuji-Mayi, D.R. Congo.
Supporting Information
Table S1 List of strains isolated from cured and relapsing
patients and their characteristics.
(DOC)
Acknowledgments
We acknowledge the medical and laboratory staff at Dipumba hospital,
supported by Minie `re de Bakwanga and by the Programme National de
Lutte contre la Trypanosomiase Humaine Africaine, for assisting in
specimen collection. We are grateful to the personnel of the animal and
cryobiology facilities at INRB for helping with the isolation experiments.
Author Contributions
Conceived and designed the experiments: PB DMN PPP NVR. Performed
the experiments: PPP DMN INL SKBS MK NVR. Analyzed the data: PB
PPP DMN INL NVR. Contributed reagents/materials/analysis tools: PB
SKBS INL MK. Wrote the paper: PPP DMN PP NVR SKBS MK.
References
1. Simarro PP, Jannin J, Cattand P (2008) Eliminating human African
trypanosomiasis: Where do we stand and what comes next? PLoS Medicine 5:
174–180.
2. Brun R, Blum J, Chappuis F, Burri C (2010) Human African trypanosomiasis.
Lancet 375: 148–159.
3. Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, et al. (2009)
Nifurtimox-eflornithine combination therapy for second-stage African Trypano-
soma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-
inferiority trial. Lancet 374: 56–64.
4. Pe ´pin J, Milord F, Khonde A, Niyonsenga T, Loko L, et al. (1994) Gambiense
trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol
therapy. Trans R Soc Trop Med Hyg 88: 447–452.
5. Robays J, Nyamowala G, Sese C, Kande Betu-Ku-Mesu V, Lutumba P, et al.
(2008) High failure rates of melarsoprol for sleeping sickness, Democratic
Republic of Congo. Em Inf Dis 14: 966–967.
6. Mumba Ngoyi D, Lejon V, Pyana P, Boelaert M, Ilunga M, et al. (2010) How to
shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping
sickness? J Infect Dis 201: 453–463.
7. Legros D, Ollivier G, Gastellu-Etchegorry M, Paquet C, Burri C, et al. (2002)
Treatment of human African trypanosomiasis - present situation and needs for
research and development. Lancet Infect Dis 2: 437–440.
8. Stanghellini A, Josenando T (2001) The situation of sleeping sickness in Angola:
a calamity. Trop Med Int Health 6: 330–334.
9. Brun R, Schumacher R, Schmid C, Kunz C, Burri C (2001) The phenomenon
of treatment failures in human African trypanosomiasis. Trop Med Int Health 6:
906–914.
10. Moore A, Richer M (2001) Re-emergence of epidemic sleeping sickness in
southern Sudan. Trop Med Int Health 6: 342–347.
11. Carter NS, Fairlamb AH (1993) Arsenical resistant trypanosome lack the
unusual adenosine transporter. Nature 361: 173–175.
12. Ma ¨ser P, Su ¨tterlin C, Kralli A, Kaminsky R (1999) A nucleoside transporter
from Trypanosoma brucei involved in drug resistance. Science 285: 242–244.
13. de Koning HP (2008) Ever-increasing complexities of diamidine and arsenical
crossresistance in African trypanosomes. Trends Parasitology 24: 345–349.
14. Maina N, Maina KJ, Ma ¨ser P, Brun R (2007) Genotypic and phenotypic
characterization of Trypanosoma brucei gambiense isolates from Ibba, South Sudan,
an area of high melarsoprol treatment failure. Acta Trop 104: 84–90.
15. Matovu E, Enyaru JCK, Legros D, Schmid C, Seebeck T, et al. (2001)
Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda.
Trop Med Int Health 6: 407–411.
16. Matovu E, Geiser F, Schneider V, Ma ¨ser P, Enyaru JCK, et al. (2001) Genetic
variants of the TbAT1 adenosine transporter from African trypanosomes in
relapse infections following melarsoprol therapy. Mol Biochem Parasitol 117:
73–81.
17. Le ´kane ´ Likeufack AC, Brun R, Fomena A, Truc P (2006) Comparison of the in
vitro drug sensitivity of Trypanosoma brucei gambiense strains from West and Central
Africa isolated in the periods 1960–1995 and 1999–2004. Acta Trop 100: 11–16.
18. Bu ¨scher P, Kahremere Bin Shamamba S, Mumba D, Pyana P, Baelmans R,
et al. (2005) Susceptibility of Grammomys surdaster thicket rats for Trypanosoma brucei
gambiense infection. Trop Med Int Health 10: 850–855.
19. Maina NW, Kunz C, Brun R (2006) Cryopreservation of Trypanosoma brucei
gambiense in a commercial cryomedium developed for bull semen. Acta Trop 98:
207–211.
20. Maina NW, Oberle M, Otieno C, Kunz C, Maeser P, et al. (2007) Isolation and
propagation of Trypanosoma brucei gambiense from sleeping sickness patients in
south Sudan. Trans R Soc Trop Med Hyg 101: 540–546.
21. Herbert WJ, Lumsden WHR (1976) Trypanosoma brucei: A rapid ‘‘matching’’
method for estimating the host’s parasitemia. Exp Parasitol 40: 427–431.
22. Radwanska M, Chamekh M, Vanhamme L, Claes F, Magez S, et al. (2002) The
serum resistance-associated gene as a diagnostic tool for the detection of
Trypanosoma brucei rhodesiense. Am J Trop Med Hyg 67: 684–690.
23. Welburn SC, Picozzi K, Fe `vre EM, Coleman PG, Odiit M, et al. (2001)
Identification of human-infective trypanosomes in animal reservoir of sleeping
sickness in Uganda by means of serum-resistance-associated (SRA) gene. Lancet
358: 2017–2019.
24. Aerts D, Truc P, Penchenier L, Claes Y, Le Ray D (1992) A kit for in vitro
isolation of trypanosomes in the field: first trial with sleeping sickness patients in
the Congo Republic. Trans R Soc Trop Med Hyg 86: 394–395.
25. Dukes P, Kaukas A, Hudson KM, Asonganyi T, Gashumba JK (1989) A new
method for isolating Trypanosoma brucei gambiense from sleeping sickness patients.
Trans R Soc Trop Med Hyg 83: 636–639.
26. Giroud C, Ottones F, Coustou V, Dacheux D, Biteau N, et al. (2009) Murine
models for Trypanosoma brucei gambiense disease progression-from silent to chronic
infections and early brain tropism. PLoS Negl Trop Dis 3: e509.
27. Schmid C, Richer M, Bilengue MMC, Josenando T, Chappuis F, et al. (2005)
Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage
human African trypanosomiasis: confirmation from a multinational study
(IMPAMEL II). J Infect Dis 191: 1922–1931.
28. Koffi M, Solano P, Barnabe C, De MT, Bucheton B, et al. (2007) Genetic
characterisation of Trypanosoma brucei s.l. using microsatellite typing: new
perspectives for the molecular epidemiology of human African trypanosomiasis.
Infect Genet Evol 7: 675–684.
29. Morrison LJ, Tait A, McCormack G, Sweeney L, Black A, et al. (2008)
Trypanosoma brucei gambiense Type 1 populations from human patients are clonal
and display geographical genetic differentiation. Infect Genet Evol 8: 847–854.
30. Jamonneau V, Garcia A, Ravel S, Cuny G, Oury B, et al. (2002) Genetic
characterization of Trypanosoma brucei gambiense and clinical evolution of human
African trypanosomiasis in Co ˆte d’Ivoire. Trop Med Int Health 7: 610–621.
T.b. gambiense from Cured and Relapsed Patients
www.plosntds.org 6 April 2011 | Volume 5 | Issue 4 | e1025